To evaluate whether DGC could penetrate BBB and further target CTGF in the brains of AD mice, we test the probe in APP/PS1 mice from 1- to 9-month-old and the age-matched WT mice for in vivo and ex vivo NIR-II imaging of brains. Here, CCN2 is linked to Alzheimer disease.